Journal
CANCER CELL
Volume 14, Issue 6, Pages 447-457Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2008.10.018
Keywords
-
Categories
Funding
- Ruth L. Kirschstein NRSA Fellowship [CA099363]
- Damon Runyon Cancer Research Foundation
- NIH [R01-CA106526]
Ask authors/readers for more resources
Deregulated Myc triggers a variety of intrinsic tumor suppressor programs that serve to restrain Myc's oncogenic potential. Since Myc activity is also required for normal cell proliferation, activation of intrinsic tumor suppression must be triggered only when Myc signaling is oncogenic. However, how cells discriminate between normal and oncogenic Myc is unknown. Here we show that distinct threshold levels of Myc govern its output in vivo: low levels of deregulated Myc are competent to drive ectopic proliferation of somatic cells and oncogenesis, but activation of the apoptotic and ARF/p53 intrinsic tumor surveillance pathways requires Myc overexpression. The requirement to keep activated oncogenes at a low level to avoid engaging tumor suppression is likely an important selective pressure governing the early stages of tumor microevolution.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available